A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

Effect of BMS-986020 on the Pharmacokinetics of Montelukast, Flurbiprofen, and Digoxin as Probe Substrates for CYP2C8, CYP2C9, and P-gp

This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.

Inclusion Criteria:

• Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive, with a body mass index of 18.0 to 32.0 kg/m2, inclusive
• Women of childbearing potential must agree to follow instructions for methods of contraception for the duration of the study

Exclusion Criteria:

• Any significant acute or chronic medical illness
• History of arrhythmias or palpitations associated with dizziness or fainting
• History of clinically relevant cardiac disease

Other protocol defined exclusion criteria could apply